Search - tctmd.com

Displaying 541 - 560 of 2684

Sort: Relevancy | Date

News Daily News

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

Yael L. Maxwell

November 21, 2022

News Daily News

Exposure to Lead Linked to Risk of CVD Mortality: Strong Heart Study

Michael O'Riordan

November 18, 2022

News Daily News

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

Michael O'Riordan

November 17, 2022

News Daily News

New Risk Models Superior to Pretest Probability at Predicting CAD

Yael L. Maxwell

November 15, 2022

News Daily News

Many STEMI Patients Not Treated Within National Time Goals

Michael O'Riordan

November 15, 2022

News Conference News AHA 2022

Drug Preconditioning Before CABG, Valve Surgery Shows Promise: START

Todd Neale

November 14, 2022

News Conference News AHA 2022

Sizeable Minority of Pregnant Women Have CVD, US Data Show

Caitlin E. Cox

November 11, 2022

News Conference News AHA 2022

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

Yael L. Maxwell

November 11, 2022

News Conference News AHA 2022

Chinese Medicine Tongxinluo Yields ‘Surprising’ Benefits Post-STEMI: CTS-AMI

Shelley Wood

November 10, 2022

News Conference News AHA 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

Todd Neale

November 10, 2022

News Conference News AHA 2022

Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI

Yael L. Maxwell

November 10, 2022

News Daily News

Heart Risks Higher With Moderna vs Pfizer/BioNTech Shot, Direct Comparison Shows

Caitlin E. Cox

November 09, 2022

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

News Conference News AHA 2022

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

Shelley Wood

November 06, 2022

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

News Conference News AHA 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

Shelley Wood

November 06, 2022

RAPCO: Radial Artery Beats of Both RITA and Vein Grafting at 15 Years

News Conference News AHA 2022

RAPCO: Radial Artery Beats Both RITA and Vein Grafting at 15 Years

Yael L. Maxwell

November 06, 2022

News Conference News AHA 2022

Early ECMO No Better Than Watch-and-Wait Approach in Cardiogenic Shock

Caitlin E. Cox

November 06, 2022

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

News Conference News AHA 2022

High-Sensitivity Troponin Testing on the Rise in the US but Still Limited

Michael O'Riordan

November 04, 2022

Advertisement

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

Exposure to Lead Linked to Risk of CVD Mortality: Strong Heart Study

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

New Risk Models Superior to Pretest Probability at Predicting CAD

Many STEMI Patients Not Treated Within National Time Goals

Drug Preconditioning Before CABG, Valve Surgery Shows Promise: START

Sizeable Minority of Pregnant Women Have CVD, US Data Show

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

Chinese Medicine Tongxinluo Yields ‘Surprising’ Benefits Post-STEMI: CTS-AMI

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI

Heart Risks Higher With Moderna vs Pfizer/BioNTech Shot, Direct Comparison Shows

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

RAPCO: Radial Artery Beats Both RITA and Vein Grafting at 15 Years

Early ECMO No Better Than Watch-and-Wait Approach in Cardiogenic Shock

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

High-Sensitivity Troponin Testing on the Rise in the US but Still Limited

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content